Acurx pharmaceuticals announces presentation of ibezapolstat phase 2 clinical trial results for cdi at scientific conference

Additional analyses of clinical and microbiological data from the phase 2b segment show favorable gut microbiome changes including increased relative proportion of actinobacteria in ibezapolstat-treated patients with c. difficile infection (cdi) results consistent with those shown in earlier human volunteer studies and phase 2a studies preservation and increased concentrations of beneficial firmicute (bacilotta) phylum known to be involved in bile acid homeostasis and short chain fatty acid metabolism was demonstrated actinobacteria and bacteroides preservation also confirmed using quantitative analysis staten island, n.y.
ACXP Ratings Summary
ACXP Quant Ranking